Douglas Criscitello, Grant Thornton LLP
Ora Dar, Israeli Life Sciences Fund
Alan Eisenberg, Biotechnology Industry Organization (BIO)
Cliff Gibbons, Gibbons & Co. (Co-Chair)
Jonathan Gruber, MIT
Debbie Lucas, MIT (Co-Chair)
Usama Malik, LRN
Leslie Platt, Platt & Associates
Jon Retzlaff, American Association for Cancer Research
Roger Stein, Moody’s
Specific Questions to be Addressed
What role can the Federal government play in supporting and regulating CanceRX?
- Federal guarantees would broaden the base of institutions that are able to invest in the megafund. What are the pros and cons of seeking federal government guarantees?
- To secure federal guarantees, what changes might be in governance, structure, prior funding review and oversight etc.?
- What types of non-guarantee assistance might the federal government provide?
- What agencies should be involved? What is the role of NIH/NCI/NCATS/VA/DoD/HHS?
- How will the SEC respond?
What roles could non-profits have in supporting CanceRX?
- Would they participate as guarantors? What are the pros and cons of non-profit guarantees vs. Federal guarantees?
- What types of non-guarantee support could they provide?
- Which non-profits are most likely to lend support?
How are current and future government policy actions likely to affect the risk and returns to investors in the megafund?
- What impact will the Affordable Care Act and other measures to bend the curve on health care cost growth have on the megafund business model?
- How are government drug pricing models and payer policies changing in light of personalized medicine?
- What will be the impact of regulatory changes/trends on the megafund model, e.g., clinical trial trends at the FDA, and what can/should a megafund do in response?
- Will the success of CanceRX create political pressures to limit a megafund’s upside?